Shipping traffic through the Strait of Hormuz remains minimal even after the US and Iran agreed to a ceasefire
Strait of Hormuz Shipping Stays Disrupted Despite US-Iran Ceasefire
Maritime activity in the Strait of Hormuz continues to be severely limited, even after the United States and Iran agreed to a temporary ceasefire. Hopes for a swift end to one of the most significant global energy supply interruptions remain low. Ship tracking reports reveal that since the announcement of a two-week halt in hostilities on Tuesday, only a small number of vessels have managed to pass through this vital waterway.
Data from the market intelligence provider Kpler shows that just five ships made the crossing on Wednesday, a sharp decrease from the eleven recorded the previous day. On Thursday, seven vessels were able to transit the strait. Meanwhile, over 600 ships—including 325 oil tankers—are still waiting, unable to proceed through the congested passage.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

